SRD5A2 Gene Polymorphisms and the Risk of Benign Prostatic Hyperplasia but not Prostate Cancer

• DOI: 10.7314/apjcp.2015.16.3.1033
• Publication Date: 2015-04-15T22:08:07Z
• Authors: Vimal Kumar Choubey; Satya Narayan San...; S. Justin Carlus; Anand Narayan Singh; Divakar Dalela; Kumarasamy Thangaraj; Singh Rajender
• Keywords: Dihydrotestosterone

Testosterone, a primary androgen in males, is converted into its most active form, dihydrotestosterone (DHT), by 5α-reductase type 2 (encoded the SRD5A2 gene) prostate. DHT necessary for prostatic growth and has five times higher binding affinity than testosterone receptors. We hypothesized that polymorphic variations gene may affect risk of benign hyperplasia prostate cancer.We analyzed polymorphisms 217 BPH patients, 192 PCa cases, 171 controls. Genotyping was undertaken using direct DNA sequencing. Genotype data were compared between cases controls Chi square statistical tool.We found A49T locus monomorphic with 'AA' genotype all subjects. At V89L locus, presence 'VV' showed marginally significant correlation increased (p=0.047). (TA)n longer TA repeats to be protective against (p=0.003). However, neither these polymoprhisms correlated PCa.We conclude study population, VV correlates risk, are BPH. None PCa.